The US Food and Drug Administration approved two cancer treatments, Vitrakvi and Xospata, this week after expedited reviews. Vitrakvi, approved Monday, is "a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker)." The FDA said in a statement that it is the second approved cancer treatment that is based on a tumor biomarker instead of the place in the body where the tumor originated.